A machine learning-derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL.
Body composition analysis (BCA) provides an objective assessment of metabolic states, but its prognostic value in diffuse large B-cell lymphoma (DLBCL) remains unclear. Taken together, our results establish baseline sarcopenia and treatment-emergent muscle loss as orthogonal risk factors for adverse outcomes in DLBCL, supporting the evaluation of BCA for risk stratification in personalized lymphoma therapy.
Body composition analysis (BCA) provides an objective assessment of metabolic states, but its prognostic value in diffuse large B-cell lymphoma (DLBCL) remains unclear. Taken together, our results establish baseline sarcopenia and treatment-emergent muscle loss as orthogonal risk factors for adverse outcomes in DLBCL, supporting the evaluation of BCA for risk stratification in personalized lymphoma therapy.
What the study was
- Study design
- Phase 3 clinical trial
- Category
- Diagnostics
- Maturity
- Potentially Practice-Changing
- Journal
- Blood advances
Why it surfaced
High-priority AI/ML in clinical diagnostics and imaging study: novel treatment potential warrants immediate pipeline escalation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.